Related Experiment Video

Updated: Aug 9, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K

Analysis of the Genetic Relationship between Atherosclerosis and Non-Alcoholic Fatty Liver Disease through Biological

Francisco Andújar-Vera1,2,3,4, María Ferrer-Millán1, Cristina García-Fontana1,2,5

  • 1Instituto de Investigación Biosanitaria de Granada (ibs. GRANADA), 18014 Granada, Spain.

International Journal of Molecular Sciences
|February 25, 2023
PubMed

Insights

This study identifies 21 common genes linking non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (ATH). Key genes like ADAMTS1 and CEBPA may be crucial for understanding and potentially treating these interconnected conditions.

Area of Science:

  • Hepatology and Cardiology
  • Molecular Biology
  • Genomics

Background:

  • Non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (ATH) share potential molecular links.
  • Understanding the molecular pathways connecting NAFLD and ATH is crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To identify common differentially expressed genes (DEGs) between NAFLD and ATH.
  • To explore the molecular mechanisms underlying the co-occurrence of NAFLD and ATH.
  • To identify potential therapeutic targets for both conditions.

Main Methods:

  • Extraction of DEGs from NAFLD (GSE89632) and ATH (GSE100927) datasets.
  • Identification of common up- and downregulated DEGs.
  • Construction of a protein-protein interaction (PPI) network.
  • Gene Ontology (GO) and pathway analysis.

Main Results:

  • Identified 21 genes with similar regulation patterns in both NAFLD and ATH.
  • ADAMTS1 (downregulated) and CEBPA (upregulated) emerged as high-centrality hub genes.
  • Two functional modules were identified: one related to post-translational protein modification (ADAMTS1, ADAMTS4) and another to immune response (CSF3).

Conclusions:

  • ADAMTS1, CEBPA, and CSF3 are identified as key proteins potentially mediating the NAFLD/ATH axis.
  • These findings offer insights into the molecular interplay between liver and vascular pathologies.
  • Further research into these factors could lead to novel therapeutic approaches for patients with co-existing NAFLD and ATH.
Keywords:
atherosclerosisnon-alcoholic fatty liver diseaseprotein–protein interaction network

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.2K
Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

3.6K

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
29
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.0K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.8K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
23
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
20